Security
Strata Skin Sciences, Inc. Common Stock · SSKN
SSKNOTCCommon stockCurrentCIK 1051514Updated Nov 16, 2026
SSKN price & chart
Loading TradingView…
OTC:SSKN on TradingView ↗About the company
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System. STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q2 2023 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 30,717,000Source | 39,383,000Source | 47,193,000Source | 30,722,000Source | 39,581,000Source | 55,204,000Source | 34,262,000Source | 40,048,000Source | 30,521,000Source | 36,157,000Source | 42,016,000Source | 52,272,000Source |
| Property, Plant and Equipment, NetUSD | 9,557,000Source | 10,387,000Source | 8,256,000Source | 8,604,000Source | 11,149,000Source | 8,319,000Source | 9,462,000Source | 11,726,000Source | 8,964,000Source | 10,061,000Source | 11,778,000Source | 7,498,000Source |
| GoodwillUSD | 1,429,000Source | 5,697,000Source | 8,803,000Source | 2,658,000Source | 6,519,000Source | 8,803,000Source | 2,658,000Source | 6,519,000Source | 1,429,000Source | 2,658,000Source | 6,519,000Source | 8,803,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 4,223,000Source | 5,840,000Source | 9,623,000Source | 4,363,000Source | 6,334,000Source | 15,959,000Source | 4,856,000Source | 6,825,000Source | 3,377,000Source | 5,348,000Source | 7,319,000Source | 17,394,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,076,000Source | 7,062,000Source | 7,131,000Source | 5,966,000Source | 5,483,000Source | 9,034,000Source | 6,512,000Source | 5,237,000Source | 7,912,000Source | 7,261,000Source | 6,784,000Source | 5,434,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,504,000Source | 4,443,000Source | 4,802,000Source | 4,022,000Source | 3,979,000Source | 4,401,000Source | 5,007,000Source | 3,630,000Source | 4,121,000Source | 5,253,000Source | 4,440,000Source | 4,471,000Source |
| Inventory, NetUSD | 3,058,000Source | 2,744,000Source | 6,125,000Source | 3,236,000Source | 2,692,000Source | 5,921,000Source | 2,659,000Source | 2,695,000Source | 2,814,000Source | 2,246,000Source | 2,673,000Source | 5,547,000Source |
| Assets, CurrentUSD | 14,272,000Source | 15,880,000Source | 19,722,000Source | 13,774,000Source | 13,825,000Source | 21,245,000Source | 15,876,000Source | 13,239,000Source | 15,600,000Source | 16,595,000Source | 15,543,000Source | 17,504,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 634,000Source | 297,000Source | 330,000Source | 550,000Source | 337,000Source | 528,000Source | 364,000Source | 343,000Source | 753,000Source | 501,000Source | 312,000Source | 691,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,005,000Source | 1,348,000Source | 718,000Source | 1,092,000Source | 1,429,000Source | 807,000Source | 1,179,000Source | 1,508,000Source | 920,000Source | 1,264,000Source | 626,000Source | 975,000Source |
| Other Assets, NoncurrentUSD | 231,000Source | 231,000Source | 71,000Source | 231,000Source | 325,000Source | 71,000Source | 231,000Source | 231,000Source | 231,000Source | 231,000Source | 231,000Source | 98,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 29,403,000Source | 29,981,000Source | 31,000,000Source | 30,414,000Source | 30,085,000Source | 38,295,000Source | 31,593,000Source | 30,616,000Source | 27,613,000Source | 31,185,000Source | 29,328,000Source | 30,441,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 5,000Source | 4,000Source | 35,000Source | 4,000Source | 4,000Source | 35,000Source | 4,000Source | 35,000Source | 6,000Source | 4,000Source | 35,000Source | 35,000Source |
| Additional Paid in CapitalUSD | 255,772,000Source | 252,986,000Source | 250,422,000Source | 253,369,000Source | 251,017,000Source | 250,085,000Source | 253,241,000Source | 250,823,000Source | 257,307,000Source | 253,112,000Source | 250,711,000Source | 249,024,000Source |
| Retained Earnings (Accumulated Deficit)USD | -254,463,000Source | -243,589,000Source | -234,264,000Source | -253,065,000Source | -241,525,000Source | -233,211,000Source | -250,576,000Source | -241,426,000Source | -254,405,000Source | -248,144,000Source | -238,058,000Source | -227,228,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,314,000Source | 9,401,000Source | 16,193,000Source | 308,000Source | 9,496,000Source | 16,909,000Source | 2,669,000Source | 9,432,000Source | 2,908,000Source | 4,972,000Source | 12,688,000Source | 21,831,000Source |
| Liabilities and EquityUSD | 30,717,000Source | 39,383,000Source | 47,193,000Source | 30,722,000Source | 39,581,000Source | 55,204,000Source | 34,262,000Source | 40,048,000Source | 30,521,000Source | 36,157,000Source | 42,016,000Source | 52,272,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 15,033,000Source | 13,165,000Source | 12,025,000Source | 14,004,000Source | 12,133,000Source | 14,120,000Source | 15,139,000Source | 12,588,000Source | 26,741,000Source | 14,625,000Source | 12,174,000Source | 13,426,000Source |
| Operating Lease, Liability, CurrentUSD | 266,000Source | 322,000Source | 404,000Source | 303,000Source | 313,000Source | 392,000Source | 331,000Source | 300,000Source | 231,000Source | 328,000Source | 352,000Source | 355,000Source |
| Accounts Payable, CurrentUSD | 2,955,000Source | 1,749,000Source | 3,157,000Source | 2,945,000Source | 2,886,000Source | 3,880,000Source | 2,816,000Source | 3,592,000Source | 2,758,000Source | 2,433,000Source | 3,343,000Source | 3,425,000Source |
| Operating Lease, Liability, NoncurrentUSD | 736,000Source | 1,002,000Source | 282,000Source | 780,000Source | 1,083,000Source | 387,000Source | 835,000Source | 1,166,000Source | 688,000Source | 919,000Source | 237,000Source | 610,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | 186,000Source | 306,000Source | — | 186,000Source | 306,000Source | — | 186,000Source | — | 0Source | 186,000Source | 306,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 6,210,000Source | 7,643,000Source | 5,901,000Source | 7,401,000Source | 6,608,000Source | 6,731,000Source | 8,779,000Source | 6,269,000Source | 6,155,000Source | 8,593,000Source | 6,306,000Source | 6,555,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 186,000Source | 306,000Source |
| Long-term Debt, Excluding Current Maturities | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Long-term Debt, Current MaturitiesUSD | 1,875,000Source | — | — | — | — | — | — | — | 15,349,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 13,435,000Source | 15,153,000Source | 15,016,000Source | 15,270,000Source | 15,114,000Source | 14,987,000Source | 15,231,000Source | 15,075,000Source | 0Source | 15,192,000Source | 15,044,000Source | 7,476,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 864,000Source | 1,239,000Source | 1,218,000Source | 1,250,000Source | 1,220,000Source | 1,249,000Source | 4,123,000Source | 4,968,000Source | 5,553,000Source | 2,400,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 129,000Source | 112,000Source | 643,000Source | 427,000Source | 1,303,000Source | 1,466,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -136,000Source | -726,000Source | -1,003,000Source | 631,000Source | -141,000Source | 1,145,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 377,000Source | 154,000Source | 288,000Source | -572,000Source | -689,000Source | 1,524,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 362,000Source | 261,000Source | 350,000Source | -954,000Source | -100,000Source | 603,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | -186,000Source | -120,000Source | 40,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -550,000Source | -804,000Source | -2,794,000Source | 188,000Source | -519,000Source | -1,108,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -199,000Source | -725,000Source | -1,468,000Source | -1,636,000Source | -5,019,000Source | -4,183,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 199,000Source | 725,000Source | 1,468,000Source | 1,636,000Source | 5,019,000Source | 3,552,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 0Source | -18,000Source | 3,579,000Source | 1,925,000Source | 6,861,000Source | -500,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -749,000Source | -1,547,000Source | -683,000Source | 477,000Source | 1,323,000Source | -5,791,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 7,076,000Source | 8,396,000Source | 5,966,000Source | 6,817,000Source | 7,846,000Source | 6,571,000Source | 7,912,000Source | 8,595,000Source | 8,118,000Source | 6,795,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 450,000Source | 480,000Source | 1,811,000Source | 1,973,000Source | 1,415,000Source | 744,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | 23,000Source | 22,000Source | 19,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 212,000Source | 26,000Source | 128,000Source | 163,000Source | 129,000Source | 112,000Source | 643,000Source | 427,000Source | 1,303,000Source | — |
| Amortization of Intangible AssetsUSD | — | — | 100,000Source | 500,000Source | 600,000Source | 500,000Source | 500,000Source | 500,000Source | 1,200,000Source | 2,000,000Source | 2,700,000Source | 2,900,000Source |
| DepreciationUSD | — | — | 700,000Source | 700,000Source | 700,000Source | 800,000Source | 700,000Source | 800,000Source | 2,900,000Source | 3,000,000Source | 2,900,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | -34,000Source | -13,000Source | -92,000Source | -49,000Source | -72,000Source | -52,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source | — | 0Source | — | — | — | 0Source | -909,000Source | — |
| General and Administrative ExpenseUSD | — | — | 2,668,000Source | 3,621,000Source | 2,911,000Source | 2,210,000Source | 2,573,000Source | 2,710,000Source | 10,184,000Source | 11,303,000Source | 10,508,000Source | 10,087,000Source |
| GoodwillUSD | — | — | 1,429,000Source | 5,697,000Source | 2,658,000Source | 6,519,000Source | 2,658,000Source | 6,519,000Source | 1,429,000Source | 2,658,000Source | 6,519,000Source | 8,803,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 3,861,000Source | 2,284,000Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 12,000Source | -170,000Source | -92,000Source | 63,000Source |
| InterestExpenseNonoperatingUSD | — | — | 498,000Source | 537,000Source | 491,000Source | 531,000Source | 486,000Source | 524,000Source | 1,959,000Source | 2,107,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | 0Source | 141,000Source | 0Source | 162,000Source | — | — |
| Investment Income, InterestUSD | — | — | 49,000Source | 68,000Source | 226,000Source | 54,000Source | 69,000Source | 45,000Source | 410,000Source | 242,000Source | 231,000Source | 89,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,622,000Source | -2,074,000Source | -2,489,000Source | -99,000Source | -2,432,000Source | -3,368,000Source | -6,261,000Source | -10,086,000Source | -10,830,000Source | -5,549,000Source |
| Nonoperating Income (Expense)USD | — | — | -449,000Source | -469,000Source | -265,000Source | 387,000Source | -417,000Source | -479,000Source | -1,549,000Source | -1,001,000Source | -2,318,000Source | -837,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | 0Source | 97,000Source | 0Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 3,579,000Source | 1,943,000Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 7,000,000Source | 0Source |
| Impairment of Intangible Assets, Finite-lived | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 6,929,000Source | 8,797,000Source | 7,663,000Source | 8,435,000Source | 6,812,000Source | 6,754,000Source | 30,696,000Source | 33,562,000Source | 33,358,000Source | 36,161,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -1,173,000Source | -1,605,000Source | -2,224,000Source | -486,000Source | -2,015,000Source | -2,889,000Source | -4,700,000Source | -9,255,000Source | -8,604,000Source | -4,649,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -6,249,000Source | -10,256,000Source | -10,922,000Source | -5,486,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 12,000Source | -170,000Source | -92,000Source | 63,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,622,000Source | -2,074,000Source | -2,489,000Source | -99,000Source | -2,432,000Source | -3,368,000Source | -6,261,000Source | -10,086,000Source | -10,830,000Source | -5,549,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.36Source | -0.51Source | -0.6Source | -0.03Source | -0.58Source | -0.96Source | -1.35Source | -2.65Source | -0.31Source | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.36Source | -0.51Source | -0.6Source | -0.03Source | -0.58Source | -0.96Source | -1.35Source | -2.65Source | -0.31Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 4,481,337Source | 4,038,988Source | 4,171,161Source | 3,506,025Source | 4,171,161Source | 3,506,025Source | 4,650,556Source | 3,807,186Source | 34,920,291Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 4,481,337Source | 4,038,988Source | 4,171,161Source | 3,506,025Source | 4,171,161Source | 3,506,025Source | 4,650,556Source | 3,807,186Source | 34,920,291Source | — |
| Interest Expense (non-operating)USD | — | — | 498,000Source | 537,000Source | 491,000Source | 531,000Source | 486,000Source | 524,000Source | 1,959,000Source | 2,107,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 100,000Source | 500,000Source | 600,000Source | 500,000Source | 500,000Source | 500,000Source | 1,200,000Source | 2,000,000Source | 2,700,000Source | 2,900,000Source |
| Costs and ExpensesUSD | — | — | 5,357,000Source | 6,891,000Source | 6,530,000Source | 5,463,000Source | 5,662,000Source | 5,969,000Source | 22,581,000Source | 28,336,000Source | 27,065,000Source | 26,417,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 12,000Source | 16,000Source | 28,000Source | 23,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 1,220,000Source | 1,249,000Source | 4,123,000Source | 4,968,000Source | 5,553,000Source | 5,293,000Source |
| General and Administrative ExpenseUSD | — | — | 2,668,000Source | 3,621,000Source | 2,911,000Source | 2,210,000Source | 2,573,000Source | 2,710,000Source | 10,184,000Source | 11,303,000Source | 10,508,000Source | 10,087,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 3,861,000Source | 2,284,000Source | 0Source |
| Gross ProfitUSD | — | — | 4,184,000Source | 5,286,000Source | 4,306,000Source | 4,977,000Source | 3,647,000Source | 3,080,000Source | 17,881,000Source | 19,081,000Source | 18,461,000Source | 21,768,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | 524,000Source | — | — | 1,640,000Source | 926,000Source |
| Investment Income, InterestUSD | — | — | 49,000Source | 68,000Source | 226,000Source | 54,000Source | 69,000Source | 45,000Source | 410,000Source | 242,000Source | 231,000Source | 89,000Source |
| Nonoperating Income (Expense)USD | — | — | -449,000Source | -469,000Source | -265,000Source | 387,000Source | -417,000Source | -479,000Source | -1,549,000Source | -1,001,000Source | -2,318,000Source | -837,000Source |
| Research and Development ExpenseUSD | — | — | 172,000Source | 243,000Source | 86,000Source | 199,000Source | 96,000Source | 241,000Source | 421,000Source | 883,000Source | 1,317,000Source | 1,029,000Source |
| Selling and Marketing ExpenseUSD | — | — | 3,201,000Source | 3,027,000Source | 3,533,000Source | 3,054,000Source | 2,993,000Source | 3,018,000Source | 13,111,000Source | 12,289,000Source | 12,956,000Source | 15,301,000Source |
Offerings
Registration 333-262150
Registration 333-273846
Registration 333-283418
Filing attachments
ef20060636_ex4-2.htm · 10-K · 2026-03-26
Exhibit 4.2 DESCRIPTION OF OUR COMMON STOCK General The following description of the material provisions of our capital stock does not purport to be complete and is based on and qualified by our Certificate of Incorporation, as amended and restated (the “Charter”), our Bylaws, and our Warrant Agreement to Purchase Shares of the Common Stock of STRATA Skin Sciences, Inc., dated as of June 30, 2023, between us and MidCap Funding XXVII Trust (“Warrant Agreement”), each of which is incorporated b…
Read attachment ↗ef20061448_ex99-1.htm · 8-K · 2025-12-17
EX-99.1 2 ef20061448_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Investor Presentation December 2025 Driving Value in Therapeutic and Aesthetic Dermatology NASDAQ: SSKN Safe Harbor Statement 2 This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statement…
Read attachment ↗ef20058935_ex99-1.htm · 8-K · 2025-11-13
EX-99.1 2 ef20058935_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and Provides a Corporate Update HORSHAM, Penn., November 13, 2025 - STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended September 30, 2025, and pr…
Read attachment ↗ea025575601ex99-1_strata.htm · 8-K · 2025-09-03
EX-99.1 5 ea025575601ex99-1_strata.htm PRICING PRESS RELEASE DATED SEPTEMBER 3, 2025 Exhibit 99.1 STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Direct Offering of Common Stock Priced At-Market Under Nasdaq Rules HORSHAM, Penn., September 3, 2025 - STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, tod…
Read attachment ↗ef20054078_ex99-1.htm · 8-K · 2025-08-18
EX-99.1 2 ef20054078_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Investor Presentation August 2025 Driving Value in Therapeutic and Aesthetic Dermatology NASDAQ: SSKN Safe Harbor Statement 2 This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements,…
Read attachment ↗ef20053890_ex99-1.htm · 8-K · 2025-08-13
EX-99.1 2 ef20053890_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update HORSHAM, Penn., August 13, 2025 - STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2025, and provides…
Read attachment ↗